You're not logged in. Please log in to earn stock or Bitcoin rewards on your prescription purchase.
Ilaris
Ilaris is the brand name for canakinumab, a human monoclonal antibody that is used to treat various autoinflammatory conditions. It specifically inhibits interleukin-1 beta (IL-1β), a cytokine that plays a crucial role in inflammation. Ilaris is primarily indicated for conditions such as cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (SJIA), and gout flares.
Oops! We currently don’t have the pricing information for this drug.
But we're continually improving our service to help you save and earn rebates on your medications. If your drug isn't listed on NiHowdy, you can still present your NiHowdy savings card at the pharmacy. We'll work to secure any eligible rebates for that drug and pass the savings back to you retroactively.
Members have saved
$NaN
using our savings card for instant savings.
Don't pay full retail price and miss out on potential savings. Try it now—you have nothing to lose!
NaNM
worth of Satoshi has been rewarded to our members.
Everyone who signs up enjoys the benefits of earning FREE Bitcoin with every purchase.
Frequently Asked Questions
How quickly does Ilaris work?
Patients may begin to notice improvements in symptoms within a few weeks of starting treatment, although full effects may take longer depending on the condition being treated.
Can I use Ilaris with other medications?
Discuss with your healthcare provider, as Ilaris can be used alone or in combination with other treatments, but some combinations may require monitoring.
Can I use Ilaris with other medications?
Discuss with your healthcare provider, as Ilaris can be used alone or in combination with other treatments, but some combinations may require monitoring.
What should I do if I miss a dose of Ilaris?
If you miss a dose, take it as soon as you remember. If it’s close to the time for your next dose, skip the missed dose and continue with your regular schedule. Do not double up on doses.
Is Ilaris safe during pregnancy?
The safety of Ilaris during pregnancy has not been fully established. Discuss with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.
Can I stop using Ilaris if my symptoms improve?
It is important to continue using Ilaris as prescribed, even if your symptoms improve. Consult your healthcare provider before making any changes to your treatment plan to ensure continued effectiveness and safety.
Comprehensive Drug Guide
How Does Ilaris Work?
Canakinumab works by specifically binding to and inhibiting IL-1β, a key pro-inflammatory cytokine involved in the regulation of immune and inflammatory responses. By blocking IL-1β, Ilaris helps to reduce inflammation and alleviate symptoms associated with various autoinflammatory diseases, improving the overall quality of life for affected individuals.
Common Dosages
- For CAPS: The recommended dose is 150 mg subcutaneously every 8 weeks for patients weighing ≥ 40 kg. For those weighing < 40 kg, the dose is 2 mg/kg every 8 weeks.
- For SJIA: The recommended dose is 400 mg subcutaneously for patients weighing ≥ 40 kg and 12 mg/kg for patients weighing < 40 kg, administered every 4 weeks.
- For gout flares: The recommended dose is 150 mg administered as a single subcutaneous injection during an acute attack.
Typical Dosing
- For CAPS: Administer 150 mg subcutaneously every 8 weeks for adults and children weighing ≥ 40 kg.
- For SJIA: Administer 400 mg subcutaneously every 4 weeks for patients weighing ≥ 40 kg or 12 mg/kg every 4 weeks for those weighing < 40 kg.
- For gout flares: Administer 150 mg as a single injection during an acute attack.
Typical Dosing
FDA Approved Indications
- Cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).
- Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.
- Gout flares in adults.
Who Shouldn't Take Ilaris?
- Known hypersensitivity to canakinumab or any components of the formulation.
- Active infections: Patients should be free from active infections before starting treatment.
Advice From The Pharmacist
- Use as prescribed: Follow your healthcare provider's instructions regarding dosage and administration schedule. Do not miss scheduled doses for optimal results.
- Monitor for side effects: Common side effects may include injection site reactions, headache, and increased risk of infections. Report any severe or unusual symptoms to your healthcare provider.
- Vaccination: Ensure that patients are up to date with vaccinations before starting treatment, as live vaccines should be avoided during therapy.
- Store Ilaris in the refrigerator and protect it from light. Do not freeze. Allow the injection to reach room temperature before administration.
Side Effects of Ilaris
Common Side Effects
- Injection site reactions (redness, swelling, pain)
- Headache
- Naua
- Fatigue
- Increased risk of infections
Uncommon/Severe Side Effects
- Severe allergic reactions (e.g., rash, itching, swelling, difficulty breathing)
- Infections: Monitoring for signs of serious infections is important, as IL-1 inhibitors can increase susceptibility to infections.
Risks and Warnings of Ilaris
- Infection Risk: Patients should be monitored for signs of infection during treatment, as Ilaris can increase the risk of serious infections.
- Live Vaccines: Patients should not receive live vaccines during treatment, and should ensure that all vaccinations are up to date.
- Monitoring: Regular follow-up appointments are important to assess the effectiveness of treatment and monitor for potential side effects.
Interactions with Ilaris
Common Drug Interactions
- Ilaris has minimal known interactions, but patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements, to prevent potential interactions.
Alternatives to Ilaris
- Other IL-1 inhibitors: Such as anakinra or rilonacept for similar conditions.
- Corticosteroids: For managing inflammatory symptoms in conditions like SJIA.
